Article

The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study.

Department of Gynecologic Oncology, Academic Medical Centre, Amsterdam, The Netherlands.
European journal of obstetrics, gynecology, and reproductive biology (impact factor: 1.97). 04/2009; 144(1):80-4. DOI:10.1016/j.ejogrb.2009.02.005 pp.80-4
Source: PubMed

ABSTRACT Low-grade endometrial stromal sarcoma (EES) is a rare tumour with a high recurrence rate but a very good prognosis. Responses to hormonal treatment of these recurrences have been published in case reports. The aim of this study was to determine the objective response rate and response duration of hormonal treatment for recurrent or residual low-grade ESS in a consecutive series of patients.
Thirteen consecutive patients with residual or recurrent disease were retrieved from the files. Eleven patients with measurable disease were treated with hormones and form the basis of this study. The following data were collected: age, date of primary diagnosis, type of primary treatment, the presence and localization of residual or recurrent disease, type of treatment, response, duration of response and survival.
After hormonal treatment 9 (82%) patients showed an objective response (4 complete response; 5 partial response), one showed stable disease (26+ months) and one progressive disease. Response duration was from 4+ to 252+ months (median 48+ months).
Hormonal treatment for measurable residual or recurrent low-grade ESS has a high response rate and should be considered as the treatment of choice for patients in which recurrent disease cannot easily be resected.

0 0
 · 
0 Bookmarks
 · 
35 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

5 partial response
 
consecutive patients
 
following data
 
good prognosis
 
hormonal treatment
 
hormonal treatment 9
 
Low-grade endometrial stromal sarcoma
 
median 48+ months
 
objective response
 
objective response rate
 
primary diagnosis
 
primary treatment
 
rare tumour
 
recurrence rate
 
recurrences
 
recurrent disease
 
recurrent low-grade ESS
 
residual low-grade ESS
 
Response duration
 
response rate